Bonesupport Holding AB (publ) (BONEX) Earnings Call Transcripts

Bonesupport Holding AB (publ)'s Latest Earnings Call - May 26, 2026

In the Q1 2026 earnings call for Bonesupport Holding AB (BONEX:SE), management highlighted a significant upward adjustment in the U.S. market potential for their product CERAMENT, particularly in the segments of foot and ankle, trauma, and arthroplasty. Revenue growth has been robust, with a reported CAGR of 55% in the U.S. since the launch of CERAMENT G in October 2022. Management maintained a positive outlook, emphasizing continued investment in clinical evidence and market penetration strategies, while also announcing plans for new studies in spine, which are expected to cost SEK 80 million over three years.

Reported metrics

Guidance from management

Management is optimistic about future growth, particularly in the U.S. market, and plans to continue investing in clinical evidence and market penetration strategies. They aim for regulatory submission for spine by 2031.

What management said

We're on time. I want to greet you to Bonesupport's Capital Markets Day for 2026. It's been around 2.5 years since we last met in November 2023. So here we are today, a warm welcome. My name is Charlotte Stjerngren. I will be the moderator of today. We have a full agenda with people from the management team, Bonesupport's CEO and also clinicians who are going to talk about the fantastic products of Bonesupport. So w...

Perfect. Thank you very much, Michael. So please stay on stage and a little perhaps you want to come up as well. So we have microphones in the room. And could we get a microphone immediately, please because Kristofer here has a question.

What analysts pressed on

Analysts expressed concerns about the slow adoption rates among surgeons and the challenges of transitioning from traditional methods to CERAMENT. There are worries about the long-term impact of these challenges on revenue growth and market share.

Main topics on the call

• Market Potential Adjustment — Management announced an upward adjustment of the market potential in the U.S. for foot and ankle, trauma, and arthroplasty, stating, "We are making an upward adjustment of the market potential that we see in the U.S." Th...
• Investment in Clinical Evidence — Bonesupport continues to invest heavily in clinical studies to support its product offerings, particularly in spine and arthroplasty. Management noted, "We are also announcing that we are going to invest in a study in ar...
• Revenue Growth — The company reported a CAGR of 55% in the U.S. since the launch of CERAMENT G, indicating strong sales momentum. Management stated, "We have delivered a 44% CAGR from 2020 to 2025," showcasing the effectiveness of their ...
• Segment-Specific Strategy — Management emphasized a shift towards a more segment-specific strategy, stating, "We want to become even more segment-specific in foot and ankle, trauma, arthroplasty and spine." This approach aims to cater to the distin...

Read the full Bonesupport Holding AB (publ) transcript (May 26, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 33 Bonesupport Holding AB (publ) earnings call transcripts on record, spanning February 26, 2020 to July 16, 2026. Based on this history, Bonesupport Holding AB (publ) reports quarterly. The most recent call on file is dated July 16, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BONEX

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

33

First call

February 26, 2020

Most recent

July 16, 2026

Reporting cadence

quarterly